Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Bastian Schilling Prof. Dr. med.

Bastian Schilling Prof. Dr. med.

Deputy Chair (Leitender Oberarzt), Department of Dermatology, University Hospital Würzburg, Germany

Dr. Bastian Schilling is Deputy Chair (Leitender Oberarzt) of the Department of Dermatology at the University Hospital of Würzburg in Germany, where he is also an associate professor in the department. 

Dr. Schilling received his medical degree from the University of Duisburg-Essen and underwent residency training in dermatology at University Hospital Essen. He completed a postdoctoral fellowship in the Department of Pathology at the University of Pittsburgh Cancer Institute, in the US. 

As a clinician treating patients with skin cancer and a scientist heading a lab concentrating on tumor immunology, Dr. Schilling focuses on skin cancer, particularly melanoma and translational melanoma research, tumor immunology and immunotherapy, and the immunological aspects of targeted therapies, among other areas of interest. 

Disclosures

Dr. Schilling is on the advisory board or has received honoraria from Immunocore, Almirall, Pfizer, Sanofi, Novartis, Roche, BMS and MSD, research funding from Novartis and Pierre Fabre Pharmaceuticals, and travel support from Novartis, Roche, Bristol-Myers Squibb and Pierre Fabre Pharma.

Recent Contributions to PracticeUpdate:

  1. Decision-Making and HRQoL in Patients With Melanoma Considering Adjuvant Immunotherapy
  2. Clinical and Molecular Response to Tebentafusp in Patients With Previously Treated Metastatic Uveal Melanoma
  3. 2022 Top Story in Advanced Melanoma: Response-Driven Therapy After Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
  4. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma
  5. Adjuvant Nivolumab Plus Ipilimumab vs Nivolumab Alone in Patients With Resected Stage IIIB–D/IV Melanoma
  6. Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Alone vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease
  7. ESMO 2022: Recommendations From Dr. Bastian Schilling for Advanced Melanoma
  8. Baseline and Post-Treatment Biomarkers of Resistance to Anti–PD-1 Therapy in Acral and Mucosal Melanoma
  9. Efficacy of Anti–PD-1 Therapy and/or Ipilimumab in Acral Melanoma
  10. Dabrafenib Plus Trametinib in Elderly Patients With BRAF V600–Mutant Advanced Melanoma

Elsewhere

Recently Updated